T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortinet
FTNT
|
+$2.03B |
| 2 |
Rockwell Automation
ROK
|
+$1.44B |
| 3 |
Autodesk
ADSK
|
+$1.15B |
| 4 |
Citigroup
C
|
+$975M |
| 5 |
ConocoPhillips
COP
|
+$967M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.59B |
| 2 |
GE Aerospace
GE
|
+$1.78B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.38B |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 5 |
Philip Morris
PM
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.21% |
| 2 | Healthcare | 15.42% |
| 3 | Financials | 10.99% |
| 4 | Consumer Discretionary | 10.39% |
| 5 | Communication Services | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Endava
DAVA
$161M
| $169M | 0.02% |
4,435,144
-3,018,188
| -40% | -$181M |
|
452
Zscaler
ZS
$29.1B
| $168M | 0.02% |
873,693
-576,452
| -40% | -$129M |
|
453
Aurora
AUR
$13.5B
| $167M | 0.02% |
59,352,847
-471,535
| -0.8% | -$1.35M |
|
454
Lattice Semiconductor
LSCC
$18.6B
| $167M | 0.02% |
2,137,142
-432,169
| -17% | -$30.9M |
|
455
Ultragenyx Pharmaceutical
RARE
$2.61B
| $167M | 0.02% |
3,568,873
+120,175
| +3% | +$5.67M |
|
456
PTC
PTC
$16B
| $165M | 0.02% |
875,282
+40,462
| +5% | +$7.29M |
|
457
Packaging Corp of America
PKG
$22.9B
| $165M | 0.02% |
869,341
+42,465
| +5% | +$7.36M |
|
458
Mettler-Toledo International
MTD
$28.6B
| $163M | 0.02% |
122,655
+57,509
| +88% | +$70.9M |
|
459
Jackson Financial
JXN
$8.96B
| $163M | 0.02% |
2,466,990
-629,850
| -20% | -$34.2M |
|
460
International Flavors & Fragrances
IFF
$21.4B
| $163M | 0.02% |
1,895,581
+162,179
| +9% | +$13M |
|
461
Main Street Capital
MAIN
$5.51B
| $163M | 0.02% |
3,439,346
+3,838
| +0.1% | +$173K |
|
462
Moody's
MCO
$82.6B
| $162M | 0.02% |
412,331
-3,166
| -0.8% | -$1.22M |
|
463
Republic Services
RSG
$65.9B
| $161M | 0.02% |
842,392
-19,555
| -2% | -$3.47M |
|
464
CDW
CDW
$17.2B
| $159M | 0.02% |
620,190
+195,951
| +46% | +$46.5M |
|
465
Immunocore
IMCR
$1.74B
| $158M | 0.02% |
2,437,584
-506,990
| -17% | -$34.8M |
|
466
Nutrien
NTR
$32.2B
| $157M | 0.02% |
2,892,488
-5,098,897
| -64% | -$266M |
|
467
Expro Ltd
XPRO
$2.06B
| $156M | 0.02% |
7,830,950
-1,570,016
| -17% | -$28.2M |
|
468
Revolution Medicines
RVMD
$43.7B
| $155M | 0.02% |
4,814,310
+177,957
| +4% | +$5.27M |
|
469
Motorola Solutions
MSI
$76.5B
| $155M | 0.02% |
435,843
+95,078
| +28% | +$31.3M |
|
470
Ionis Pharmaceuticals
IONS
$9.29B
| $153M | 0.02% |
3,522,203
-732,871
| -17% | -$34.9M |
|
471
CoStar Group
CSGP
$12.5B
| $151M | 0.02% |
1,567,199
-1,701
| -0.1% | -$146K |
|
472
Strategy Inc
MSTR
$37.9B
| $151M | 0.02% |
887,620
+108,350
| +14% | +$9.88M |
|
473
Acadia Realty Trust
AKR
$2.85B
| $151M | 0.02% |
8,848,246
+388,067
| +5% | +$6.53M |
|
474
Idexx Laboratories
IDXX
$44.5B
| $150M | 0.02% |
277,516
+90
| +0% | +$49.2K |
|
475
Extra Space Storage
EXR
$31.4B
| $149M | 0.02% |
1,014,718
-1,765,911
| -64% | -$257M |
|
Similar funds
T. Rowe Price Associates's Q1 2024 Portfolio in Review
As of Q1 2024, T. Rowe Price Associates held 3,021 positions worth $816B, up 9.6% from $744B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q1 2024 filing shows 108 new, 1,941 increased, 738 reduced and 64 closed positions. Its largest new stake was GE Vernova: 2,687,194 shares worth $367M. The largest sale was NVIDIA, an estimated $2.59B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2024 buy was GE Vernova: 2,687,194 shares worth $367M.
- T. Rowe Price Associates added most to Fortinet in Q1 2024, an estimated $2.03B increase.
- T. Rowe Price Associates's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $2.59B.
- T. Rowe Price Associates fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $621M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $816B portfolio in Q1 2024.
- T. Rowe Price Associates opened 108 new positions and closed 64 in Q1 2024.
- T. Rowe Price Associates's portfolio value rose 9.6% quarter-over-quarter to $816B.
Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.